Preparation, characterization and in vitro cytotoxicity evaluation of free and liposome-encapsulated tylosin

Saddiqi, Mohammad Ehsan; Kadir, Arifah Abdul; Abdullah, Faez Firdaus Jesse; Zakaria, Md Zuki Abu Bakar; Banke, Idris Sherifat

doi:10.1016/j.onano.2022.100108

Cited by 3 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In terms of public health, effective control of biofilm growth by S. epidermidis and other bacteria associated with medical devices is crucial for reducing rates of hospital-acquired infections and improving the safety of medical procedures [40]. Incorporating antibiotics into liposomes, such as Tylosin, is also a promising strategy for effectively treating antibioticresistant bacterial pathogens [41].…”

Section: Nanoparticle-liposome Hybrid Systems: Revolutionizing Pharma...mentioning

confidence: 99%

Revolutionizing Therapy: Nanomaterials in Liposomes Redefine the Future of Medicinal Drugs

M. Oliveira,

M.F. Duarte,

de L. Lins

et al. 2024

Liposomes - A Modern Approach in Research [Working Title]

View full text Add to dashboard Cite

Liposomes are microscopic lipid-based vesicles that have emerged as a promising vehicle for transporting therapeutic agents with precision and efficiency. From enhanced drug bioavailability to targeted delivery, combining nanomaterials and liposomes offers a transformative approach to therapeutic interventions. Encapsulating nanomaterials with drugs in liposomes holds immense significance as it enhances precision, efficiency, and targeted delivery, revolutionizing therapeutic interventions in medicine. This chapter delves into the unique properties of nanomaterials encapsulated within liposomes, examining their potential to revolutionize medicine. In addition, it highlights key advancements, challenges, and prospects in this dynamic and rapidly evolving field, providing readers with a comprehensive understanding of the revolutionary impact on the future of medicinal drugs.

show abstract

Section: Nanoparticle-liposome Hybrid Systems: Revolutionizing Pharma...mentioning

confidence: 99%

Revolutionizing Therapy: Nanomaterials in Liposomes Redefine the Future of Medicinal Drugs

M. Oliveira,

M.F. Duarte,

de L. Lins

et al. 2024

Liposomes - A Modern Approach in Research [Working Title]

View full text Add to dashboard Cite

show abstract

Ameliorative delivery of docetaxel and curcumin using PEG decorated lipomers: A cutting-edge in-vitro/ in-vivo appraisal

Tariq,

Hassan,

Ali

et al. 2024

Journal of Drug Delivery Science and Technology

View full text Add to dashboard Cite

Liposomal Formulation of an Organogold Complex Enhancing Its Activity as Antimelanoma Agent—In Vitro and In Vivo Studies

Pinho,

Coelho,

Pimpão

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Background/Objectives: The therapeutic management of melanoma, the most aggressive form of skin cancer, remains challenging. In the search for more effective therapeutic options, metal-based complexes are being investigated for their anticancer properties. Cisplatin was the first clinically approved platinum-based drug and, based on its success, other metals (e.g., gold) are being used to design novel compounds. Methods: the antimelanoma potential of a new organometallic cyclometalated Au(III) complex [[Au(CNOxN)Cl2] (CNOxN = 2-(phenyl-(2-pyridinylmethylene)aminoxy acetic acid))] (ST004) was evaluated in vitro and in vivo. Furthermore, the gold-based complex was incorporated in liposomes to overcome solubility and stability problems, to promote accumulation at melanoma sites and to maximize the therapeutic effect while controlling its reactivity. The antiproliferative activity of ST004 formulations was assessed in murine (B16F10) and human (A375 and MNT-1) melanoma cell lines after 24 and 48 h incubation periods. The proof-of-concept of the antimelanoma properties of ST004 formulations was carried out in subcutaneous and metastatic murine melanoma models. Results: the developed liposomal formulations showed a low mean size (around 100 nm), high homogeneity (with a low polydispersity index) and high incorporation efficiency (51 ± 15%). ST004 formulations exhibited antiproliferative activity with EC50 values in the μmolar range being cell-line- and incubation-period-dependent. On the opposite side, the benchmark antimelanoma compound, dacarbazine (DTIC), presented an EC50 > 100 μM. Cell cycle analysis revealed an arrest in G0/G1 phase for Free-ST004 in all cell lines. In turn, LIP-ST004 led to a G0/G1 halt in B16F10, and to an arrest in S phase in A375 and MNT-1 cells. Preliminary mechanistic studies in human red blood cells suggest that gold-based inhibition of glycerol permeation acts through aquaglyceroporin 3 (AQP3). In a metastatic murine melanoma, a significant reduction in lung metastases in animals receiving LIP-ST004, compared to free gold complex and DTIC, was observed. Conclusion: This study highlights the antimelanoma potential of a new gold-based complex. Additional studies, namely in vivo biodistribution profile and therapeutic validation of this organogold complex in other melanoma models, are expected to be performed in further investigations.

show abstract

Preparation, characterization and in vitro cytotoxicity evaluation of free and liposome-encapsulated tylosin

Cited by 3 publications

References 45 publications

Revolutionizing Therapy: Nanomaterials in Liposomes Redefine the Future of Medicinal Drugs

Revolutionizing Therapy: Nanomaterials in Liposomes Redefine the Future of Medicinal Drugs

Ameliorative delivery of docetaxel and curcumin using PEG decorated lipomers: A cutting-edge in-vitro/ in-vivo appraisal

Liposomal Formulation of an Organogold Complex Enhancing Its Activity as Antimelanoma Agent—In Vitro and In Vivo Studies

Contact Info

Product

Resources

About